Overview
Xiaoling Hu practices practicing medicine in Hangzhou, China.
Their clinical expertise encompasses Alport Syndrome, Hepatitis B, Infertility, and Breast Cancer.
They are actively involved in clinical research, co-authoring 19 peer reviewed articles.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Xiaoling Hu
Is Xiaoling Hu a top-rated expert for Alport Syndrome?
MediFind is an objective health platform that identifies experts based on real-world data. Xiaoling Hu is classified as an Experienced expert for Alport Syndrome, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Xiaoling Hu participate in research or clinical trials?
Yes. Xiaoling Hu has published 19 articles and abstracts on conditions like Alport Syndrome. You can view a list of Xiaoling Hu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Alport SyndromeHu isExperienced. Learn about Alport Syndrome.
- Breast CancerHu isExperienced. Learn about Breast Cancer.
- HepatitisHu isExperienced. Learn about Hepatitis.
- Hepatitis BHu isExperienced. Learn about Hepatitis B.
- InfertilityHu isExperienced. Learn about Infertility.
- Ovarian Hyperstimulation Syndrome
- Triple-Negative Breast Cancer